In 2024, Fierce Biotech reported 192 industry layoff rounds, which is 3% higher than in 2023, when 187 rounds were tallied. Rounds are reported as they are disclosed and are not combined per ...

“From Ground Zero” is a rare work for which superlatives are not only inadequate but useless. It’s an anthology of 22 short subject by Palestinians living in the Israeli-occupied Gaza Strip. Most are ...

Re­gen­eron, mak­er of the block­buster oph­thal­mol­o­gy med­i­cine Eylea, has ac­quired an oc­u­lar biotech, the large bio­phar­ma con­firmed to End­points News on Thurs­day.

No Oxular employees are joining Regeneron, though several will be “helping short-term with tech transfer and transition work in consulting roles,” a Regeneron spokesperson told Fierce Biotech ...

2024 was the year of the pri­vate megaround. Nine-fig­ure fi­nanc­ings dom­i­nat­ed biotech’s ven­ture fund­ing land­scape, with 96 such rounds tal­lied by End­points News. The bevy … ...

Carmell acquires Elevai Skincare, adding $2.5M in annual revenue and advanced exosome technology to its portfolio. Deal includes $1.1M in equity, $57K in cash, and earnouts tied to sales and ...

The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies have slowed. An anticipated upswing in initial public offerings hasn’t ...

However, China’s influence in global R&D has grown significantly, with expanding clinical trial activity and first-to-market launches. All the news that moves the needle in pharma and biotech ...